<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250220</url>
  </required_header>
  <id_info>
    <org_study_id>18-779</org_study_id>
    <nct_id>NCT04250220</nct_id>
  </id_info>
  <brief_title>eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial (eBRAVE-AF)</brief_title>
  <acronym>eBRAVE-AF</acronym>
  <official_title>eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial (eBRAVE-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Preventicus GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Versicherungskammer Bayern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common arrhythmia in western countries and causes of up
      to one quarter of ischemic strokes. The randomized eHealth-based Bavarian Alternative
      Detection of Atrial Fibrillation study (eBRAVE-AF) tests the efficacy of an e-health based
      strategy for the detection of AF. The e-health-based strategy consists of a smartphone-based
      photophlethysmographic (PPG) screening and an ECG-based validation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with newly diagnosed atrial fibrillation within six months with prescription of oral anticoagulation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with newly diagnosed atrial fibrillation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with newly prescribed oral anticoagulation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with stroke</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with thromboembolic events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with TIMI major bleeding</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>e-health-based strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>symptom based AF-screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>e-Health based strategy: PPG-based screening using a smartphone and ECG patch</intervention_name>
    <description>PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  policy holders of a large health insurance company

          -  age ≥50 years

          -  CHA2DS2-VASc ≥1 (females ≥2)

        Exclusion Criteria:

          -  atrial fibrillation

          -  oral anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axel Bauer, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73172</phone_ext>
    <email>axel.bauer@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luisa Freyer, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73172</phone_ext>
    <email>luisa.freyer@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Bauer, MD</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>73172</phone_ext>
      <email>axel.bauer@med.uni-uenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Luisa Freyer, MD</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>73172</phone_ext>
      <email>luisa.freyer@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Axel Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Rizas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Freyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Axel Bauer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

